GLP-1 and mental health: why psychological assessment matters during weight-loss treatment

For patients considering or already using GLP-1-based weight-loss medication, this means that good medical care involves more than choosing a drug and adjusting its dose.

It means treating the person, not only their weight.

Do GLP-1 medications affect mental health?

This has become one of the important questions surrounding the rapidly expanding use of GLP-1 medications.

So far, the most robust evidence is broadly reassuring.

A 2025 systematic review and meta-analysis published in JAMA Psychiatry included 80 randomized clinical trials involving 107,860 participants. Researchers found no significant increase in either serious or non-serious psychiatric adverse events among patients receiving GLP-1 receptor agonists compared with placebo.

Interestingly, GLP-1 treatment was associated with improvements in several measures, including emotional eating, restrained eating and mental health-related quality of life. The researchers cautioned that more evidence is still needed in psychiatric populations.

Another JAMA Psychiatry meta-analysis examined suicide and self-harm specifically. Across randomized trials, these events were very rare, with no statistically significant difference between GLP-1 receptor agonists and placebo.

The authors nevertheless recommended continued monitoring, particularly because some clinical trials excluded people with previous depression or suicidal behavior.

The short answer

Current evidence does not show that GLP-1 medications generally increase psychiatric adverse events.

But psychiatric safety and psychological care are not the same question.

A medication can have a reassuring overall psychiatric safety profile while an individual patient may still benefit from assessment of their mental health, eating behavior and expectations before and during treatment.

And this distinction is becoming increasingly important.

New 2026 guidance puts psychological wellbeing into GLP-1 care

One of the most important recent developments came from three European organizations: the European Association for the Study of Obesity (EASO), European Federation of the Associations of Dietitians (EFAD) and European Coalition for People Living with Obesity (ECPO).

Their 2026 consensus statement, published in The Lancet Diabetes & Endocrinology, addresses nutritional, functional and psychological considerations for adults receiving incretin-based therapies.

The experts recognize the substantial benefits of these medications while pointing out that reduced appetite, rapid weight loss, gastrointestinal adverse effects and changes in eating behavior can create nutritional, functional or psychological challenges for some people.

The recommendations therefore emphasize long-term behavioral support, psychological wellbeing and person-centered obesity care rather than medication in isolation.

This represents an important shift in how GLP-1 treatment is discussed.

The question is no longer simply: “Which medication will help this patient lose weight?”

It is increasingly: “What does this individual patient need to achieve a safe, sustainable health outcome?”

Why mental health matters before starting semaglutide or tirzepatide

Obesity is a chronic disease, not a failure of willpower.

At the same time, eating is not governed exclusively by metabolic signals.

People eat in response to hunger and satiety, but eating behavior can also interact with stress, emotions, habits, social situations and psychological wellbeing.

This becomes particularly relevant when treatment substantially changes appetite.

Some patients describe a dramatic reduction in hunger or persistent thoughts about food after starting GLP-1-based treatment. For many people this can be beneficial.

But patients do not all enter treatment from the same starting point.

A physician may therefore need to understand whether there is a history of problematic restriction or disordered eating, how the patient currently relates to food, whether depression or anxiety is affecting daily life, what previous weight-loss attempts looked like and what the patient expects medication to achieve.

Psychological assessment does not mean that every person considering GLP-1 therapy needs a psychiatric evaluation.

It means that psychological health should not disappear from medical decision-making simply because an effective medication is available.

“We are treating a patient, not a number on the scale”

This is particularly important in clinical practice, according to Dr Andrei Popov, an Oladoctor physician with extensive experience managing patients receiving GLP-1-based therapies.

“When we assess a patient for GLP-1 therapy, we are not treating a number on the scale. We need to understand the patient's health, previous attempts to lose weight, eating behavior, expectations and treatment goals. Psychological wellbeing is part of that picture.”

Two people with a similar BMI can have very different medical histories and very different reasons for seeking treatment.

One may have obesity-related metabolic complications and realistic expectations about gradual treatment.

Another may already be severely restricting food or may expect medication to produce a particular appearance or body weight that is not clinically appropriate.

That distinction matters.

“The same medication does not mean the same treatment plan for every patient. Assessment and follow-up allow us to understand not only whether the medication is working, but how the patient is responding to treatment as a whole,” says Dr Popov.

GLP-1 treatment should not be medication alone

This principle extends beyond European recommendations.

In its first global guideline on GLP-1 therapies for obesity, published in December 2025, the World Health Organization described obesity as a chronic, relapsing disease and conditionally recommended GLP-1 therapies as a long-term treatment option for adults living with obesity.

Importantly, WHO also recommended integrating treatment with behavioral and lifestyle support rather than viewing medication as a standalone solution.

That matters because the goals of obesity treatment extend beyond achieving a particular number on a scale.

Treatment may involve metabolic health, nutrition, physical function, side-effect management, preservation of lean mass, eating behavior, quality of life and psychological wellbeing.

What should a doctor assess before GLP-1 treatment?

There is no single psychological checklist appropriate for every patient. Assessment should be individualized.

Depending on the patient's history and circumstances, a medical consultation may include discussion of:

• current health conditions and medications;

• previous attempts at weight management;

• eating patterns and relationship with food;

• previous or current eating-disorder symptoms;

• depression, anxiety or other relevant mental-health history;

• reasons for seeking weight-loss treatment;

• expectations about the amount and speed of weight loss;

• possible contraindications and risk factors;

• ability to maintain adequate nutrition during appetite suppression;

• plans for medical monitoring and long-term treatment.

A patient's answers do not automatically determine whether they can or cannot receive medication. They give the physician a more complete clinical picture from which to make an individualized decision.

What about patients who already take antidepressants or have anxiety or depression?

Having a mental-health condition does not automatically mean that a person cannot receive GLP-1 therapy.

The appropriate decision depends on the individual patient's medical history, current condition, other medications and the specific GLP-1-based treatment being considered.

This is one area where individualized assessment is particularly important.

Randomized evidence to date is reassuring at the population level, but researchers have also pointed out an important limitation: people with certain psychiatric histories have sometimes been excluded from clinical trials.

Patients should therefore tell the prescribing physician about relevant mental-health conditions and medications rather than assuming they are unrelated to weight-management treatment.

Why follow-up matters after treatment begins

Assessment should not end when the first prescription is issued.

During treatment, the clinical picture can change.

A physician may need to evaluate treatment response, side effects, nutritional intake, changes in eating behavior, dose tolerance, weight trajectory and the patient's overall physical and psychological wellbeing.

This becomes particularly important as treatment progresses and appetite changes.

The 2026 European consensus specifically emphasizes comprehensive support throughout incretin-based therapy, including nutrition, preservation of physical function, management of gastrointestinal effects, long-term behavior change and psychological wellbeing.

Can you discuss GLP-1 treatment with a doctor online?

For many patients, an online medical consultation can be an appropriate first step for discussing weight-management treatment.

A physician can review the patient's medical history, current medications, previous treatment, weight-management goals and relevant risk factors and determine what further assessment may be necessary.

Whether a particular medication is appropriate — and whether a prescription can be issued — remains an individual clinical decision.

At Oladoctor, patients can consult doctors experienced in GLP-1-based weight management, including Dr Andrei Popov, online.

The aim is not simply to obtain a prescription. A consultation provides an opportunity to discuss whether treatment may be appropriate, how it should be monitored and what medical, nutritional or psychological factors should be considered.

Book an online GLP-1 consultation

The next phase of GLP-1 treatment is more personal

The rapid development of GLP-1 and related therapies has given clinicians powerful new options for treating obesity.

The next challenge is using those tools well.

Current evidence provides reassurance about the overall psychiatric safety of GLP-1 receptor agonists. At the same time, the newest European recommendations make an equally important point: psychological wellbeing belongs inside comprehensive obesity care.

For patients, that means GLP-1 treatment should be more than obtaining medication.

It should involve understanding the patient's health, goals, eating behavior, treatment response and long-term needs.

As the evidence evolves, one principle is becoming increasingly clear:

Successful GLP-1 treatment is not simply about losing weight. It is about improving health in a way that is safe, individualized and sustainable.